Sieta T de Vries (Sieta de Vries)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 28

Top Topics

Transcription Factor

Cross Sectional

Top Venues

Pharmacoepidemiology and drug safety

Diabetic medicine : a journal of the British Diabetic Association

Journal of clinical medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Sieta T de Vries, Stijn de Vos, Monika Pury Oktora, Petra Denig
Sex disparities in medication changes after metformin initiation are associated with small, clinically non-relevant, sex differences in HbA1c levels during follow-up. Pharmacoepidemiology and drug safety 33 (5) (2024)
Sieta T de Vries, Stijn de Vos, Monika Pury Oktora, Petra Denig
Sex disparities in medication changes after metformin initiation are associated with small, clinically non-relevant, sex differences in HbA1c levels during follow-up. Pharmacoepidemiology and drug safety 33 (5) (2024)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Monika Pury Oktora, Stijn de Vos, Sieta T de Vries, Eelko Hak, Petra Denig
Sex disparities in treatment patterns after metformin initiation among patients with type 2 diabetes mellitus. Pharmacoepidemiology and drug safety (2023)
Sieta T de Vries, Noral Huda S Al-Mugoter, Irena Petkoska, Stefan Verweij, André J A Elferink, Peter G M Mol
Comment on: "The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022". Applied health economics and health policy (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Sonia Roldan Munoz, Douwe Postmus, Sieta T de Vries, Liana Gross-Martirosyan, Priya Bahri, Hans L Hillege, Peter G M Mol
What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug safety 46 (3) (2023)
Martina Ambrož, Marit Geelink, Kirsten P J Smits, Sieta T de Vries, Petra Denig
Sex disparities in medication prescribing amongst patients with type 2 diabetes mellitus managed in primary care. Diabetic medicine : a journal of the British Diabetic Association (2022)
Sieta T de Vries, Viktoriia Starokozhko, Ingrid M M Schellens, Leonoor Wijnans, Harald Enzmann, Marco Cavaleri, Peter G M Mol
Attention for sex in COVID-19 trials: a review of regulatory dossiers. BMJ global health 7 (3) (2022)
Esther de Vries, Petra Denig, Sieta T de Vries, Taco B M Monster, Jacqueline Geertruida Hugtenburg, Peter G M Mol
Drug Safety Issues Covered by Lay Media: A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands. Drug safety 43 (7) (2021)
Sieta T de Vries, Petra Denig, Corine Ekhart, Peter G M Mol, Eugene P van Puijenbroek
Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study. Drug safety 43 (5) (2021)
Carla J Jonker, Sieta T de Vries, H Marijke van den Berg, Patricia McGettigan, Arno W Hoes, Peter G M Mol
Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Study Among Industry and Other Stakeholders. Drug safety 44 (8) (2021)
Martina Ambrož, Sieta T de Vries, Priya Vart, Robin P F Dullaart, Jeanine E Roeters van Lennep, Petra Denig, Klaas Hoogenberg
Sex Differences in Lipid Profile across the Life Span in Patients with Type 2 Diabetes: A Primary Care-Based Study. Journal of clinical medicine 10 (8) (2021)
Sieta T de Vries, Petra Denig, Adriana Andrić, Marina Dimov Di Giusti, Alicia Ptaszynska-Neophytou, Linda Härmark, Peter G M Mol, null null
Motives to Report Adverse Drug Reactions to the National Agency: A Survey Study among Healthcare Professionals and Patients in Croatia, The Netherlands, and the UK. Drug safety 44 (10) (2021)
Martina Ambrož, Sieta T de Vries, Grigory A Sidorenkov, Klaas Hoogenberg, Petra Denig
Changes in blood pressure thresholds for initiating antihypertensive medication in patients with diabetes: a repeated cross-sectional study focusing on the impact of age and frailty. BMJ open 10 (9) (2020)
Martina Ambrož, Sieta T de Vries, Klaas Hoogenberg, Petra Denig
Trends in HbA1c thresholds for initiation of hypoglycemic agents: Impact of changed recommendations for older and frail patients. Pharmacoepidemiology and drug safety 30 (1) (2020)
Sieta T de Vries, Judy Harrison, Patrick Revelle, Alicia Ptaszynska-Neophytou, Anna Radecka, Gowthamei Ragunathan, Phil Tregunno, Petra Denig, Peter G M Mol
Use of a Patient-Friendly Terms List in the Adverse Drug Reaction Report Form: A Database Study. Drug safety 42 (7) (2020)
Petra Denig, Eugene P van Puijenbroek, Nashwa Soliman, Peter G M Mol, Sieta T de Vries
Adverse drug event patterns experienced by patients with diabetes: A diary study in primary care. Pharmacoepidemiology and drug safety 28 (9) (2019)
Sieta T de Vries, Petra Denig, Corine Ekhart, Jako S Burgers, Nanne Kleefstra, Peter G M Mol, Eugene P van Puijenbroek
Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study. British journal of clinical pharmacology 85 (7) (2019)
Corine Ekhart, Florence P A M van Hunsel, Joep H G Scholl, Sieta T de Vries, Eugene P van Puijenbroek
Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors. Drug safety 41 (7) (2018)
Sieta T de Vries, Petra Denig, Carmen Lasheras Ruiz, François Houÿez, Lisa Wong, Alastair Sutcliffe, Peter G M Mol, null null
Interest in a Mobile App for Two-Way Risk Communication: A Survey Study Among European Healthcare Professionals and Patients. Drug safety 41 (7) (2018)
Sieta T de Vries, Maartje J M van der Sar, Amelia Cupelli, Ilaria Baldelli, Anna Marie Coleman, Dolores Montero, Ivana Šipić, Adriana Andrić, Annika Wennberg, Jane Ahlqvist-Rastad, Petra Denig, Peter G M Mol, null null
Communication on Safety of Medicines in Europe: Current Practices and General Practitioners' Awareness and Preferences. Drug safety 40 (8) (2018)
Sieta T de Vries, Maartje J M van der Sar, Anna Marie Coleman, Yvette Escudero, Alfonso Rodríguez Pascual, Miguel-Ángel Maciá Martínez, Amelia Cupelli, Ilaria Baldelli, Ivana Šipić, Adriana Andrić, Line Michan, Petra Denig, Peter G M Mol, null null
Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study. Drug safety 41 (7) (2018)
Sieta T de Vries, Lisa Wong, Alastair Sutcliffe, François Houÿez, Carmen Lasheras Ruiz, Peter G M Mol, null null
Factors Influencing the Use of a Mobile App for Reporting Adverse Drug Reactions and Receiving Safety Information: A Qualitative Study. Drug safety 40 (5) (2017)